Navigation Links
Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
Date:12/17/2009

- BioMS Medical makes strategic investment of $12 million in Spectral -

TORONTO and EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) and BioMS Medical Corp. (TSX: MS) today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.

Spectral obtained exclusive rights for the Toraymyxin(TM) device in the US from Toray Industries Inc., of Japan, in March of 2009 and, following the closing of the financing (the "Closing"), anticipates initiating a pivotal US clinical trial in the first half of 2010. Toraymyxin(TM) has been used in more than 70,000 patients globally and has demonstrated in clinical trials that it safely and effectively removes endotoxin and reduces mortality in patients with severe sepsis. There are approximately 125,000 patients who develop endotoxemia related severe sepsis in the US each year and who currently face a high risk of mortality with limited treatment options, representing a potential market opportunity in excess of $1 billion per annum.

"We are now focused on obtaining clearance from the FDA to initiate the pivotal US trial - a randomized double blinded prospective trial, comparing standard of care versus standard of care plus Toraymyxin (TM), in patients with proven endotoxemia," said Dr. Paul Walker, President and CEO of Spectral. "The resources from this investment, combined with the clinical, regulatory and capital market expertise of the BioMS team, will assist Spectral to effectively conduct its anticipated pivotal trial in the US."

"The use of a specific diagnostic test, the EAA(TM), to identify endotoxin, a substance that is known to be harmful to the body, and proceed to remove it with the Toraymyxin(TM) column makes this
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. First Spaceborne Hyperspectral Imager Will Use QImaging Rolera-MGi EMCCD Camera
2. Spectral appoints new board member
3. Spectral announces second quarter 2009 results
4. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
5. Spectral announces first quarter 2009 results
6. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
7. Spectral announces 2008 financial results
8. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
9. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
10. Spectral announces third quarter 2008 results
11. Spectral to bring anti-sepsis therapy to the U.S. market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a ... manufacture and sale of enzyme and protein products ... today announced financial results for the quarter ended ... this press release should be read in conjunction ...
... SynCo Bio Partners B.V., one of the leading GMP contract ... is again fully operational and SynCo has produced and released ... expansion of its Class A zone.   The ... in SynCo,s strategy in supporting its clients with new product ...
... for gram, novel carbon nanofiber-filled coatings devised by researchers ... and Texas A&M University outperformed conventional flame retardants used ... by at least 160 percent and perhaps by as ... reported in the journal Polymer ,* suggest that ...
Cached Biology Technology:Dyadic International Reports 2011 Second Quarter Financial Results 2Dyadic International Reports 2011 Second Quarter Financial Results 3Dyadic International Reports 2011 Second Quarter Financial Results 4Dyadic International Reports 2011 Second Quarter Financial Results 5Dyadic International Reports 2011 Second Quarter Financial Results 6Dyadic International Reports 2011 Second Quarter Financial Results 7SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Novel coatings show great promise as flame retardants in polyurethane foam 2
(Date:4/15/2014)... 2014, Irvine, Calif. UC Irvine neurobiologists have found ... when transplanted into the brains of mice with the ... is published in the journal Stem Cells Research ... to work in two different mouse models. , ... dementia, is associated with accumulation of the protein amyloid-beta ...
(Date:4/15/2014)... know as early as 2020 how high sea levels ... team of researchers including Florida International University scientist Rene ... Science Foundation,s (NSF) Florida Coastal Everglades Long-Term Ecological Research ... in ecosystems from coral reefs to deserts, mountains to ... sea level rise is one of the most certain ...
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
Breaking Biology News(10 mins):UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Long-term predictions for Miami sea level rise could be available relatively soon 2Biologists develop nanosensors to visualize movements and distribution of plant hormone 2
... insect brains, mouth bacteria behaving badly and the hundreds ... just some of the highlights at the Society for ... The annual event takes place on 6-9 September at ... international experts will present cutting-edge scientific research covering a ...
... Carolina State University shows that a species of shellfish widely ... actually increased in size, despite and possibly because of ... found indicates that human activity does not necessarily mean that ... species even a species that people relied on as ...
... filter-feeder, that anchors itself to the sea bed, offers new ... Ice Sheet a region that is thought to be ... for the Census of Antarctic Marine Life (CAML), scientists from ... coastal and deep sea regions around the continent and from ...
Cached Biology News:Archaeological study shows human activity may have boosted shellfish size 2Marine animals suggest evidence for a trans-Antarctic seaway 2
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Leucine-rich repeat-containing G-protein coupled receptor 4...
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
Biology Products: